Informa plc (LSE:INF)  is preparing to launch an auction process to sell its clinical trial data provider Citeline in a deal that could value the business at up to £1.2 billion ($1.63 billion), sources familiar with the matter told Reuters. The firm has hired Goldman Sachs to sell the business and is expected to send out confidential information packages between the end of January 2022 and early February 2022, the sources said, speaking on condition of anonymity. Centerview is working with Goldman on the sale, another source said, adding that the asset generates around £75 million in core earnings.

Informa, Goldman Sachs and Centerview declined to comment.